Do we consider enough the presence of triggering factors in the evaluation of patients with FMF? Triggering factors are highly prevalent in colchicine-resistant FMF patients
- PMID: 38103114
- DOI: 10.1007/s11739-023-03486-3
Do we consider enough the presence of triggering factors in the evaluation of patients with FMF? Triggering factors are highly prevalent in colchicine-resistant FMF patients
Abstract
The aim of the study is to investigate the frequency of triggering factors in colchicine-resistant and -responsive Familial Mediterranean Fever (FMF) patients as well as the effect of interleukin (IL)-1 antagonist treatment on the triggering factors. Both colchicine-resistant (patients on IL-1 antagonist treatment) and colchicine-responsive (patients on colchicine who had ≤ 3 attacks in the last year) patients were questioned for the presence of 12 different triggering factors, including exposure to cold, emotional stress, fatigue, physical activity, menstruation (for females), sleeplessness, prolonged standing, long-duration travel, high-fat diet intake, starvation, infection, and trauma. Colchicine-resistant patients were questioned for the presence of triggering factors for two time periods, before and after treatment with IL-1 antagonists. We studied 28 colchicine-resistant and 35 colchicine-responsive patients. Overall 77.8% of patients had at least one triggering factor. Triggering factors were associated with 28.5% of the total number of attacks. More than half of the patients (57.1%) declared that they had avoided these conditions. The frequency of triggering factors was higher in the colchicine-resistant group as compared to the colchicine-responsive group (89.3% vs 68.6%; p = 0.04). In colchicine-resistant FMF patients, the frequency of triggering factors (89.3% vs 32.1%) and the percentage of attacks initiated by triggering factors (27.8 vs 14.4%; p < 0.001) were decreased after treatment with IL-1 antagonists. In this study, triggering factors were more frequent in colchicine-resistant patients as compared to colchicine-responsive patients. Treatment with IL-1 antagonists seems to increase the endurance of colchicine-resistant patients in stressful conditions.
Keywords: Colchicine-resistance; FMF; IL-1 antagonist; Triggering factors.
© 2023. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).
Similar articles
-
Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.Mod Rheumatol. 2017 Mar;27(2):350-355. doi: 10.1080/14397595.2016.1194510. Epub 2016 Jun 22. Mod Rheumatol. 2017. PMID: 27328763
-
Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.Int J Rheum Dis. 2020 Jul;23(7):977-981. doi: 10.1111/1756-185X.13891. Epub 2020 Jun 18. Int J Rheum Dis. 2020. PMID: 32558310
-
Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.Trials. 2018 Dec 29;19(1):715. doi: 10.1186/s13063-018-3105-6. Trials. 2018. PMID: 30594222 Free PMC article.
-
[INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].Harefuah. 2015 Nov;154(11):716-9, 741. Harefuah. 2015. PMID: 26821505 Review. Hebrew.
-
The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.Front Immunol. 2020 May 28;11:971. doi: 10.3389/fimmu.2020.00971. eCollection 2020. Front Immunol. 2020. PMID: 32670263 Free PMC article. Review.
Cited by
-
Factors triggering familial mediterranean fever attacks, do they really exist?Intern Emerg Med. 2024 Jun;19(4):1007-1013. doi: 10.1007/s11739-024-03576-w. Epub 2024 Mar 15. Intern Emerg Med. 2024. PMID: 38488998 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources